Axsome Therapeutics, Inc. (AXSM) SEC Filings, Feb 2-28, 2026

AXSM affiliate intends to sell 35,378 shares of Class A Common stock on 02/26/2026. The shares were acquired as compensation (stock options) and the planned method is a cashless exercise / same-day sale through Goldman Sachs & Co. LLC.

Axsome Therapeutics, Inc. director Mark Coleman reported exercising stock options and holding the resulting shares. On February 23, 2026, he exercised options covering 6,250 shares of common stock at $4.95 per share for cash, and kept the underlying shares rather than selling them. Following these transactions, he directly owned 72,140 shares of Axsome common stock and indirectly beneficially owned 403,856 shares held through an entity over which he has voting and dispositive power.

Axsome Therapeutics director Mark Coleman exercised stock options and increased his share exposure to the company. On February 20, 2026, he exercised 12,485 stock options at an exercise price of $4.95 per share for cash, receiving the same number of Axsome common shares, which he held rather than selling.

After the transactions, Coleman holds 65,890 shares of common stock directly and 13,971 stock options directly. He is also reported as the indirect beneficial owner of 403,856 common shares held by an entity over which he has voting and dispositive power.

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on central nervous system disorders, with three FDA‑approved U.S. products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness in obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute migraine.

Total revenues from these three products reached $638.5 million in 2025, a 66% increase over 2024, reflecting rapid commercial ramp. The company is advancing a broad late‑stage pipeline, including AXS‑05 for Alzheimer’s disease agitation under FDA Priority Review with a PDUFA target date of April 30, 2026, multiple Phase 3 programs for solriamfetol in ADHD, depression with daytime sleepiness, binge eating disorder, and shift work disorder, and AXS‑12 for narcolepsy supported by positive Phase 2 and 3 data and Orphan Drug status.

Axsome is also developing AXS‑14 for fibromyalgia following an earlier Refusal to File, and AXS‑17 for epilepsy acquired via the Baergic Bio transaction. As of February 16, 2026, the company had 51,153,289 common shares outstanding and reported extensive global patent coverage and settled generic challenges that generally protect key franchises into the late 2030s and early 2040s.

Axsome Therapeutics reported strong growth for the fourth quarter and full year 2025, with total net product revenue of $196.0 million in Q4 and $638.5 million for the year, up 65% and 66% from 2024. Growth was led by AUVELITY with 2025 sales of $507.1 million and SUNOSI with $124.8 million, plus initial SYMBRAVO contributions of $6.6 million.

The company’s net loss narrowed to $183.2 million in 2025 from $287.2 million in 2024, despite higher SG&A spending of $570.6 million to support commercialization. Cash and cash equivalents were $322.9 million as of December 31, 2025.

Axsome highlighted a rich CNS pipeline, including Priority Review for its sNDA for AXS-05 in Alzheimer’s disease agitation with a PDUFA target date of April 30, 2026, an NDA submission for AXS-12 in narcolepsy planned this quarter, multiple Phase 3 solriamfetol trials, and the newly acquired epilepsy candidate AXS-17.

Axsome Therapeutics has entered into a settlement agreement with Alkem Laboratories resolving U.S. patent litigation over Axsome’s wake‑promoting drug SUNOSI (solriamfetol). The case arose after Alkem filed an Abbreviated New Drug Application seeking approval to market a generic SUNOSI in the United States.

Under the settlement, Axsome will grant Alkem a license to sell its generic SUNOSI beginning on or after September 1, 2040 if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040 if no pediatric exclusivity is granted, in each case subject to FDA approval and customary conditions. The settlement will be submitted to the FTC and DoJ for review, and Axsome notes that similar patent litigation against another party regarding SUNOSI remains pending in the same court.

Axsome Therapeutics director Mark Coleman reported an option exercise and related share holdings. On February 10, 2026, he exercised 5,193 stock options at an exercise price of $8.02 per share and held the underlying common stock rather than selling it. Following this transaction, he directly owned 53,405 shares of common stock. In addition, 403,856 shares of common stock are held indirectly through an entity over which he has voting and dispositive power, so he is deemed the indirect beneficial owner of those shares.

Axsome Therapeutics CEO Herriot Tabuteau reported an option exercise and share sale. On 02/02/2026, he exercised 32,410 stock options at $8.02 per share and acquired the same number of common shares. That same day, he sold 32,410 common shares at a weighted average price of $185.60 under a pre-approved Rule 10b5-1 plan that has now been completed.

After these transactions, Tabuteau directly holds 7,229 shares of Axsome common stock and is also deemed the indirect beneficial owner of 7,344,500 additional shares held by an entity over which he has voting and dispositive power.

Axsome Therapeutics insider plans to sell common stock. A Form 144 notice reports a proposed sale of 32,410 shares of Axsome Therapeutics common stock through Goldman Sachs & Co. LLC, with an aggregate market value of 6,024,370.8, to be sold on or about 02/02/2026 on NASD.

The shares were acquired on 05/27/2016 as compensation via stock options and will be disposed of through a cashless exercise and same-day sale. The filing lists 50,412,640 common shares outstanding and details additional common stock sales by Herriot Tabuteau over the past three months.